Since then, multiple ICIs against PD-1, such as pembrolizumab53,54 and nivolumab,55,56 have been approved by the FDA for use in the treatment of certain cancers, with the list of targeted cancers growing over time.52 This evidence concerns the gene PDCD1 and cancer.